Evolus Inc (EOLS)

Currency in USD
7.86
-0.15(-1.87%)
Closed·
7.860.00(0.00%)
·

EOLS Earnings

Latest Release
Aug 05, 2026
EPS / Forecast
-0.12 / -0.04
Revenue / Forecast
84.08M / 81.89M
EPS Revisions
Last 90 days
Release Date
Period End
EPS
/Forecast
Revenue
/Forecast
EPS Surprise %
Revenue Surprise %
Reaction
2026/09--/-0.068--/77.78M----Free Sign Up
2026/06-0.120/-0.04084.08M/81.89M-200%+2.67%Free Sign Up
2026/03-0.160/-0.11073.10M/72.46M-45.45%+0.88%Free Sign Up
2025/120.044/0.04090.30M/90.75M+10.5%-0.5%Free Sign Up
2025/09-0.240/-0.15069.00M/67.69M-60%+1.94%Free Sign Up
2025/06-0.270/-0.10069.39M/82.18M-170%-15.56%Free Sign Up
2025/03-0.300/-0.09068.50M/72.51M-233.33%-5.53%Free Sign Up
2024/12-0.110/0.02079.00M/76.96M-650%+2.65%Free Sign Up
2024/09-0.300/-0.12061.10M/63.18M-150%-3.29%Free Sign Up
2024/06-0.180/-0.05066.90M/64.93M-260%+3.03%Free Sign Up

All numbers in USD

Evolus Inc Earnings Call Summary for Q2/2026

  • Q2 revenue rose 21% YoY to $84.1M, beating estimates of $81.89M, though EPS loss of $0.12 missed forecasts by $0.08 per share.
  • Evolus raised 2026 revenue guidance floor to $330M from prior level, maintaining $337M ceiling; reaffirmed 2028 target of $450M-$500M revenue.
  • Company posted third consecutive quarter of positive adjusted EBITDA at $4.7M with 68% gross margin, signaling improving profitability.
  • Evolysse Sculpt approval expected Q4 2026; Profhilo skin-quality product added via partnership, targeting $100M+ peak annual revenue by 2030.
  • Accounts purchasing both Jeuveau and Evolysse bought 2.5x more volume, validating multi-product platform strategy amid rising operating expenses.
Last Updated: 2026-08-05, 05:32 p/m
Read Full Transcript

FAQ

What Is Evolus's Earnings Per Share (TTM)?

The Evolus EPS (TTM) is -0.53.

When Is The Next Evolus Earnings Date?

Evolus will release its next earnings report on Nov 10, 2026.

What Is Evolus’s Revenue Forecasts For Upcoming Quarters?

Evolus’s revenue forecast is 77.78M.

How Did Evolus React to the Company's Latest Earnings Report?

Evolus reported a -200% EPS surprise and a +2.67% revenue surprise, comparing the latest report against analyst forecasts. The stock price changed by 21.08%, reflecting the market's response to the earnings results.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.